Vaccines

1. Front Matter

   Pages i-viii

   PDF

2. Dendritic Cells in the Induction of Immunity

   • Stella C. Knight

   Pages 1-6

3. Escape Mechanisms of Viruses from Immune Responses and Their Relevance to Vaccine Design

   • Jean-Louis Virelizier

   Pages 7-12

4. Enhanced Immunogenicity of Recombinant and Synthetic Peptide Vaccines

   • M. J. Francis

   Pages 13-23

5. Immunomodulation by Adjuvants

   • R. Bomford, M. Stapleton, S. Winsor

   Pages 25-32

6. Use of Syntex Adjuvant Formulation to Enhance Immune Responses to Viral Antigens

   • N. E. Byars, G. M. Nakano, M. Welch, A. C. Allison

   Pages 33-42

7. Influenza Vaccines and the Wyeth-Ayerst Experience with Syntex Adjuvant

   • Richard N. Hjorth, Geraldine M. Bonde, Elizabeth D. Piner, Kenneth M. Goldberg, Daniel M. Teller, Mark Hite et al.

   Pages 43-58

8. Nonionic Block Polymer Surfactants as Adjuvants in Vaccines

   • Guy J. W. J. Zigterman, Andre F. M. Verheul, Harm Snippe

   Pages 59-75

9. Effects of Added Cytokines on Immune Responses and Memory

   • A. W. Heath, J. H. L. Playfair

   Pages 77-84

10. The Assessment and Use of Adjuvants

    • D. E. S. Stewart-Tull

    Pages 85-92

11. Efficient Anti-Idiotypic Immunization with Homologous, Virus Neutralizing Monoclonal Antibodies Conjugated with KLH and Combined with Quil A

    • Tom A. M. Oosterlaken, Theo Harmsen, Cornelis A. Kraaijeveld, Harm Snippe

    Pages 93-98

12. Protein Conformation Affects the Efficacy of Pertussis Vaccines

    • A. Bartoloni, M. G. Pizza, A. Covacci, D. Nucci, L. Nencioni, R. Rappuoli

    Pages 99-105

13. Vaccination Against Epstein-Barr Virus

    • M. A. Epstein

    Pages 107-112

14. Adenovirus Vectored Vaccines

    • K-H. Hsu, M. Lubeck, S. Mizutani, R. Natuk, M. Chengalvala, P. Chanda et al.

    Pages 113-119

15. Vaccines Against Bacterial Infections of Children

    • P. Helena Makela, Helena Kayhty, Aino K. Takala, Heikki Peltola, Juhani Eskola

    Pages 121-135

16. Current Progress and Future Trends in Birth Control Vaccines

    • Norbert Dreifurst, Avrion Mitchison

    Pages 137-143

17. Back Matter

    Pages 145-154

    PDF

The success of vaccination in controlling infectious diseases is well documented. However, low profitability, expense and liability have hindered research and development of vaccines. Recently, increasing realization (enhanced by the AIDS pandemic) of the need to overcome such difficulties has led to steps being taken by national authorities, non-profit and commercial organizations to resolve them. This has been facilitated by developments in recombinant DNA techniques, the advent of monoclonal anti­ bodies and progress in the understanding of the immunological structure of proteins which have laid the foundation of a new generation of vaccines. Such vaccines are defined at the molecular level, can elicit immune responses controlling infectious organisms and are therefore potentially free of the problems encountered in conventional ones. Unfortunately, subunit and synthetic peptide vaccines are often only weakly or non­ inmunogenic. However, developments in both antigen production and immuno­ potentiation of weak antigens have opened new avenues with exciting prospects for vaccine design.

• AIDS
• Antigen
• development
• diseases
• infectious disease
• proteins
• research
• vaccine

• School of Pharmacy, University of London, London, UK

  Gregory Gregoriadis

• Syntex Research, Palo Alto, USA

  Anthony C. Allison

• SmithKline Beecham Pharmaceuticals, King of Prussia, USA

  George Poste

Policies and ethics